SGMO — Sangamo Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00
- $103.78m
- $22.78m
- $176.23m
- 21
- 51
- 42
- 31
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -95.4 | -121 | -178 | -192 | -258 |
Depreciation | |||||
Amortisation | |||||
Deferred Taxes | |||||
Non-Cash Items | 14.4 | 32.7 | 37.5 | 38.9 | 188 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | -73 | 253 | -102 | -82.3 | -164 |
Change in Accounts Receivable | |||||
Change in Prepaid Expenses | |||||
Change in Accrued Expenses | |||||
Change in Payable / Accrued Expenses | |||||
Change in Other Liabilities | |||||
Cash from Operating Activities | -144 | 170 | -233 | -224 | -225 |
Capital Expenditures | -20.7 | -14.7 | -23.3 | -20.2 | -21.2 |
Purchase of Fixed Assets | |||||
Other Investing Cash Flow Items | -39.1 | -257 | 271 | 79.5 | 175 |
Acquisition of Business | |||||
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | -59.8 | -272 | 248 | 59.3 | 154 |
Financing Cash Flow Items | -0.422 | -0.765 | -3.26 | -2.1 | -1.45 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Cash from Financing Activities | 142 | 153 | 32.9 | 84.7 | 14.6 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | -62 | 50.9 | 47.5 | -78.4 | -55.2 |